Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

NCT03734211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Cardiac Allograft Vasculopathy

Interventions

DRUG: Evolocumab
DRUG: Placebo

Sponsor

Lars Gullestad

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]